(CercleFinance.com) – Strata Oncology today announced the extension of its clinical collaboration with Pfizer in the Strata Precision Indications for Approved Therapies trial.
Strata PATH is a prospective, pan-tumor therapeutic trial designed to evaluate the efficacy and safety of several FDA-approved cancer therapies in novel patient populations guided by biomarkers.
Pfizer will provide Braftovi (encorafenib), Mektovi (binimetinib) and Lorbrena (lorlatinib) to up to six new cohorts of patients with lung, melanoma, colorectal and other early-stage cancers with evidence of micrometastasis after the initial treatment.
“Our goal is to deliver smarter, earlier treatment to every patient and having the support of Pfizer is a testament to the potential of the clinical trials we use to accelerate the impact of precision oncology,” said Dan Rhodes, Ph.D., co-founder and CEO of Strata Oncology.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
